Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening...
Published in: | Blood Cancer Journal |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Nature Publishing Group
2021
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/621875 https://doi.org/10.1038/s41408-021-00480-w |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/621875 |
---|---|
record_format |
openpolar |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
Mergæxli Skimun Multiple Myeloma Iceland Mass Screening |
spellingShingle |
Mergæxli Skimun Multiple Myeloma Iceland Mass Screening Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G M Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. |
topic_facet |
Mergæxli Skimun Multiple Myeloma Iceland Mass Screening |
description |
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy. Black Swan Research Initiative by the International Myeloma Foundation Icelandic Centre for Research European Research Council (ERC) University of Iceland Landspitali University Hospital |
author2 |
1Faculty of Medicine, Univeristy of Iceland, Reykjavík, Iceland. 2Dept of Hematology, Rigshospitalet, Copenhagen, Denmark. 3Landspítali University Hospital, Reykjavík, Iceland. 4Faculty of Psychology, University of Iceland, Reykjavik, Iceland. 5Akureyri Hospital, Akureyri, Iceland. 6Faculty of Economics, University of Iceland, Reykjavik, Iceland. 7The Binding Site, Birmingham, West Midlands, UK. 8Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9Cedar-Sinai Samual Oschin Cancer Center, Los Angeles, CA, USA. 10Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. 11Faculty of Medicine, Univeristy of Iceland, Reykjavík, Iceland. sigyngvi@hi.is. 12Landspítali University Hospital, Reykjavík, Iceland. sigyngvi@hi.is. |
format |
Article in Journal/Newspaper |
author |
Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G M Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi |
author_facet |
Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G M Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi |
author_sort |
Rögnvaldsson, Sæmundur |
title |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. |
title_short |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. |
title_full |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. |
title_fullStr |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. |
title_full_unstemmed |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. |
title_sort |
iceland screens, treats, or prevents multiple myeloma (istopmm): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. |
publisher |
Nature Publishing Group |
publishDate |
2021 |
url |
http://hdl.handle.net/2336/621875 https://doi.org/10.1038/s41408-021-00480-w |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Blood cancer journal 11 5 94 United States |
op_relation |
https://www.nature.com/articles/s41408-021-00480-w https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128921/ Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Eyþórsson E, Jónsson Á, Björnsson AS, Gunnarsson GÞ, Pálsson R, Indriðason ÓS, Gíslason GK, Ólafsson A, Hákonardóttir GK, Brinkhuis M, Halldórsdóttir SL, Ásgeirsdóttir TL, Steingrímsdóttir H, Danielsen R, Dröfn Wessman I, Kampanis P, Hulcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021 May 17;11(5):94. doi:10.1038/s41408-021-00480-w. 34001889 doi:10.1038/s41408-021-00480-w http://hdl.handle.net/2336/621875 2044-5385 Blood cancer journal |
op_rights |
Open Access - Opinn aðgangur |
op_doi |
https://doi.org/10.1038/s41408-021-00480-w |
container_title |
Blood Cancer Journal |
container_volume |
11 |
container_issue |
5 |
_version_ |
1766036837155995648 |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/621875 2023-05-15T16:46:44+02:00 Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G M Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi 1Faculty of Medicine, Univeristy of Iceland, Reykjavík, Iceland. 2Dept of Hematology, Rigshospitalet, Copenhagen, Denmark. 3Landspítali University Hospital, Reykjavík, Iceland. 4Faculty of Psychology, University of Iceland, Reykjavik, Iceland. 5Akureyri Hospital, Akureyri, Iceland. 6Faculty of Economics, University of Iceland, Reykjavik, Iceland. 7The Binding Site, Birmingham, West Midlands, UK. 8Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9Cedar-Sinai Samual Oschin Cancer Center, Los Angeles, CA, USA. 10Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. 11Faculty of Medicine, Univeristy of Iceland, Reykjavík, Iceland. sigyngvi@hi.is. 12Landspítali University Hospital, Reykjavík, Iceland. sigyngvi@hi.is. 2021-09 http://hdl.handle.net/2336/621875 https://doi.org/10.1038/s41408-021-00480-w en eng Nature Publishing Group https://www.nature.com/articles/s41408-021-00480-w https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128921/ Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Eyþórsson E, Jónsson Á, Björnsson AS, Gunnarsson GÞ, Pálsson R, Indriðason ÓS, Gíslason GK, Ólafsson A, Hákonardóttir GK, Brinkhuis M, Halldórsdóttir SL, Ásgeirsdóttir TL, Steingrímsdóttir H, Danielsen R, Dröfn Wessman I, Kampanis P, Hulcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021 May 17;11(5):94. doi:10.1038/s41408-021-00480-w. 34001889 doi:10.1038/s41408-021-00480-w http://hdl.handle.net/2336/621875 2044-5385 Blood cancer journal Open Access - Opinn aðgangur Blood cancer journal 11 5 94 United States Mergæxli Skimun Multiple Myeloma Iceland Mass Screening Article 2021 ftlandspitaliuni https://doi.org/10.1038/s41408-021-00480-w 2022-05-29T08:22:39Z To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy. Black Swan Research Initiative by the International Myeloma Foundation Icelandic Centre for Research European Research Council (ERC) University of Iceland Landspitali University Hospital Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive Blood Cancer Journal 11 5 |